Lung cancer chemotherapy can be divided into radical chemotherapy, palliative chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, local chemotherapy and chemotherapy for sensitization. Radical chemotherapy is mainly used in the treatment of SCLC, which is characterized by adequate amount and course of combined chemotherapy, in order to achieve the ultimate goal of long-term survival or cure. Palliative chemotherapy is mainly used for advanced lung cancer, which is characterized by delaying the development of lesions, reducing the symptoms of patients, improving the quality of life and prolonging the survival time. Neoadjuvant chemotherapy is preoperative chemotherapy, which is used to transform lesions into operable ones, and at the same time, it is expected to improve long-term survival rate by reducing micrometastases. Adjuvant chemotherapy is chemotherapy after complete resection, which is expected to improve the survival rate by reducing micrometastases, especially to improve the tumor-free survival time. 5.Localized chemotherapy: The chemotherapeutic drugs are injected directly into the bronchial artery or blood vessels of the lesion under the image-mediated process, so as to form a high intratumoral drug concentration to improve the therapeutic effect. Sensitization chemotherapy is carried out at the same time of radiotherapy in order to enhance the sensitivity of tumor cells to radiotherapy.